BioAtla, Inc. (BCAB) Tuesday said that the Food and Drug Administration or FDA has granted fast track designation to ozuriftamab vedotin, the company's drug candidate for the treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based chemotherapy and anti-PD-1/L1 antibody therapy.
Fast Track Designation could lead to actions to expedite development and review of the drug, including opportunities for frequent interactions with the FDA review team and potential priority review if criteria are met.
In the Phase 2 study, ozuriftamab vedotin has shown promising clinical activity with a manageable safety profile in treatment-refractory SCCHN patients.
The company said it is on track to meet with the FDA for guidance on a potentially registrational trial in the second half of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.